FDA Policy and Cardiovascular Medicine-Reference-Cited by-同舟云学术

FDA Policy and Cardiovascular Medicine

Published:2015-09-22 Issue:12 Volume:132 Page:1136-1145
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Ross Joseph S.¹,Kesselheim Aaron S.¹

Affiliation:

1. From Section of General Internal Medicine and the Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine; Department of Health Policy and Management, Yale University School of Public Health; and Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, CT (J.S.R.); and Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.114.010295

Reference99 articles.

1. US Food and Drug Administration. FDA organizational histories. August 2013. http://www.fda.gov/AboutFDA/WhatWeDo/History/FOrgsHistory/default.htm. Accessed January 7 2015.

2. Federal Food and Drugs Act Pub L No. 59-384 34 Stat 768 (1906).

3. Federal Food Drug and Cosmetic Act Pub L No. 75-717 52 Stat 1040 (1938).

4. Drug Amendments Act Pub L No. 87–781 76 Stat 780 (1962).

5. Medical Device Amendments Pub L No. 94–295 90 Stat 539 (1976).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018;Clinical Trials;2021-04-16

2. U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018;2020-09-02

3. Clinical Evidence Supporting FDA Clearance of First-of-a-Kind Therapeutic Devices via the De Novo Pathway Between 2011 and 2019;2020-04-29

4. Clear Evidence Clarified;SSRN Electronic Journal;2020

5. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments;JAMA Network Open;2019-05-10